Evidence map›Paper›PMID 31293106›Full record

ArticleMolecular genetics & genomic medicine2019

Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort.

Alana C Cecchi, Elizabeth S Vengoechea, Kristjan E Kaseniit, Melanie W Hardy, Laura A Kiger, Nikita Mehta, Imran S Haque, Krista Moyer, Patricia Z Page, Dale Muzzey and 1 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Molecular genetics & genomic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Alana C CecchiMyriad Women's Health, South San Francisco, California.
Elizabeth S VengoecheaDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.
Kristjan E KaseniitMyriad Women's Health, South San Francisco, California.
Melanie W HardyDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0003-3126-5979
Laura A KigerMyriad Women's Health, South San Francisco, California.
Nikita MehtaMyriad Women's Health, South San Francisco, California.
Imran S HaqueMyriad Women's Health, South San Francisco, California.
Krista MoyerMyriad Women's Health, South San Francisco, California.
Patricia Z PageDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.
Dale MuzzeyMyriad Women's Health, South San Francisco, California.ORCID 0000-0001-8822-2035
Karen A GrinzaidDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.ORCID 0000-0003-2158-8846
Myriad (Germany) · DEEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathogenic variants in HEXA that impair β-hexosaminidase A (Hex A) enzyme activity cause Tay-Sachs Disease (TSD), a severe autosomal-recessive neurodegenerative disorder. Hex A enzyme analysis demonstrates near-zero activity in patients affected with TSD and can also identify carriers, whose single functional copy of HEXA results in reduced enzyme activity relative to noncarriers. Although enzyme testing has been optimized and widely used for carrier screening in Ashkenazi Jewish (AJ) individuals, it has unproven sensitivity and specificity in a pan-ethnic population. The ability to detect HEXA variants via DNA analysis has evolved from limited targeting of a few ethnicity-specific variants to next-generation sequencing (NGS) of the entire coding region coupled with interpretation of any discovered novel variants.

methodsWe combined results of enzyme testing, retrospective computational analysis, and variant reclassification to estimate the respective clinical performance of TSD screening via enzyme analysis and NGS. We maximized NGS accuracy by reclassifying variants of uncertain significance and compared to the maximum performance of enzyme analysis estimated by calculating ethnicity-specific frequencies of variants known to yield false-positive or false-negative enzyme results (e.g., pseudodeficiency and B1 alleles).

resultsIn both AJ and non-AJ populations, the estimated clinical sensitivity, specificity, and positive predictive value were higher by NGS than by enzyme testing. The differences were significant for all comparisons except for AJ clinical sensitivity, where NGS exceeded enzyme testing, but not significantly.

conclusionsOur results suggest that performance of an NGS-based TSD carrier screen that interrogates the entire coding region and employs novel variant interpretation exceeds that of Hex A enzyme testing, warranting a reconsideration of existing guidelines.

Indexed as

beta-Hexosaminidase alpha ChainCohort StudiesEnzyme AssaysEthnicityFalse Negative ReactionsFalse Positive ReactionsGenetic Carrier ScreeningGenetic CounselingHeterozygoteHigh-Throughput Nucleotide SequencingHumansMutationPolymorphism, Single NucleotidePractice Guidelines as TopicRetrospective StudiesSensitivity and Specificitybeta-Hexosaminidase alpha ChainHEXA protein, humancarrier screeningHEXA enzyme testingTay-Sachs diseasevariant interpretationVUS reclassification

Identifiers

PMID31293106
PMCPMC6687860
OpenAlexW2959284463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.